{"id":"NCT03287960","sponsor":"Rhythm Pharmaceuticals, Inc.","briefTitle":"Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity","officialTitle":"An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Leptin Receptor (LEPR) Deficiency Obesity Due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-30","primaryCompletion":"2020-09-25","completion":"2020-09-25","firstPosted":"2017-09-19","resultsPosted":"2023-05-23","lastUpdate":"2023-05-23"},"enrollment":15,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Leptin Receptor Deficiency Obesity"],"interventions":[{"type":"DRUG","name":"Setmelanotide","otherNames":["RM-493"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Setmelanotide","type":"EXPERIMENTAL"}],"summary":"To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with LEPR deficiency obesity due to rare bi-allelic or loss-of function mutations at the end of 1 year of treatment.","primaryOutcome":{"measure":"Percentage of Participants Who Reached â‰¥10% Weight Loss Threshold After 1 Year (Pivotal Cohort)","timeFrame":"Week 52","effectByArm":[{"arm":"Setmelanotide (Entire Study)","deltaMin":45.5,"sd":null}],"pValues":[{"comp":"OG000","p":"0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["Canada","France","Germany","Netherlands","Reunion","United Kingdom"]},"refs":{"pmids":["33137293"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":15},"commonTop":["Injection site erythema","Skin hyperpigmentation","Injection site pruritus","Nausea","Injection site induration"]}}